Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
2018
The field of tumor immunology has faced many complex challenges over the last century, but the approval of
immune checkpointinhibitors (anti-cytotoxic T-lymphocyte-associated protein 4 [CTLA4] and anti-
programmed cell death-1 [PD-1]/PD-ligand 1 [
PD-L1]) and
talimogene laherparepvec(T-VEC) for the treatment of metastatic melanoma have awakened a new wave of interest in
cancer immunotherapy. Additionally, combinations of vaccines and oncolytic
viral therapieswith
immune checkpointinhibitors and other systemic agents seem to be promising synergistic strategies to further boost the immune response against cancer. These combinations are undergoing
clinical investigation, and if successful, will hopefully soon become available to patients. Here, we review key basic concepts of tumor-induced immune suppression in malignant melanoma, the historical perspective around vaccine development in melanoma, and advances in oncolytic
viral therapies. We also discuss the emerging role for combination approaches with different immunomodulatory agents as well as new developments in personalized immunization approaches.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
81
References
9
Citations
NaN
KQI